TriCipher Press Releases

Pharmaceutical and Health Care Experts to Detail Cost-Cutting Capabilities of Secure Digital Signatures

Dec. 16 Webinar Features Executives from TriCipher, SAFE-BioPharma and Pfizer

LOS GATOS, Calif. (Dec. 16, 2008) - TriCipher will host an informative Webinar detailing the cost cutting capabilities of digital signatures for the pharmaceutical and health care industries and strategies for securing digital signatures as more business processes transition online. The one hour webinar on December 16th brings together executives from SAFE-BioPharma Association and Pfizer who will discuss how digital signatures have benefited and streamlined research processes.

"Digital signatures represent the 'last mile' in moving business processes online for the pharmaceutical and health care industries," said Jon Brody, vice president of marketing at TriCipher. "Through the work of industry associations like SAFE-BioPharma and enabling technology companies like TriCipher, it's now possible to bridge that gap."

Participants that attend the Webinar will learn:

• How businesses have saved hundreds of thousands of dollars by no longer needing to handle paper-based signatures
• The benefits of streamlining submissions to FDA and other regulatory agencies
• Strategies for protecting intellectual property and delivering a long term solution to IP preservation
• The 'Green' benefits of digital signatures

WHO:	Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association William Barnes, Director of Identity Services, Pfizer Jon Brody, vice president of marketing, TriCipher A managing director of identity services at a leading international systems integrator
WHAT:	"Cutting Costs with Digital Signatures in the Biopharmaceutical Industry"
WHEN:	Tuesday, December 16th, 11 a.m. – 12 p.m. PT
WHERE:	To register please visit: https://www2.gotomeeting.com/register/792964500

The webinar will include a brief demonstration of digital signatures using TriCipher's MySignatureBook with SAFE-BioPharma credentials. For more information on MySignatureBook and the webinar, please visit www.Tricipher.com.


###


About TriCipher
TriCipher, Inc. provides a unified authentication infrastructure to protect web and enterprise portals, the people that use them and the business process that flows through them against fraud and identity theft. The TriCipher Armored Credential System™ (TACS) is the first authentication system that enables companies to deploy and manage multiple types of credentials from a single infrastructure. Through this flexible "Authentication Ladder," TriCipher protects customer investment by adjusting authentication strength to defeat new threats and to meet regulatory changes without the need to implement a new infrastructure. Recently, TriCipher introduced myOneLogin™ the first secure on-demand offering that delivers strong authentication, single sign-on (SSO) convenience and the ability to seamlessly integrate multiple Software as a Service (SaaS) applications in a single solution. Founded in 2000, TriCipher is headquartered in Los Gatos, Calif. The company is funded by ArrowPath Venture Capital, EPIC Ventures, Intel Capital, RBC Technology Ventures, and Trident Capital. For more information, visit TriCipher on the web at www.tricipher.com.


About MySignatureBook
TriCipher mySignatureBook™ is a web-based digital signing solution that gathers multiple signatures from a centrally managed, Web-based workflow to a single, unaltered document. mySignatureBook ensures end-to-end security for highly regulated and sensitive documents, and eliminates time-consuming and costly paper-based signature processes, including shipping and storage. mySignaureBook supports a range of MSB supports a variety of strong credentials, including TriCipher clientless credentials, SAFE™ credentials, TriCipher ID Tool and ID Tool ToGo and any PKCS#11 digital credential. . A robust web services interface makes it easy to integrate MSB with a variety of applications and document management systems.

About SAFE-BioPharma
SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma™ digital identity and signature standard for the pharmaceutical and healthcare industries. The SAFE-BioPharma industry standard is used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions. It facilitates interoperability by providing a secure, enforceable, and regulatory-compliant way to verify identities of parties involved in electronic transactions. SAFE-BioPharma’s vision is to be a catalyst in transforming the biopharmaceutical and healthcare communities to a fully electronic business environment by 2012. The Association’s members include Amgen (NASDAQ: AMGN), AstraZeneca (NYSE: AZN), Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. For more information, www.safe-biopharma.org.

SAFE-BioPharma™ is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.

All product and company names herein may be trademarks of their registered owners.

Media Contacts:
Dan Brennan
Corporate Ink
617.969.9192
dbrennan@corporateink.com